RN7SL850P

Across TCGA pan-cancer cohorts, RN7SL850P RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RN7SL850P’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RN7SL850P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL850P is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

BLCA, KIRC, and STAD are the cancer types where RN7SL850P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL850P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.178	.008	5	view →
KIRC	All	III,IV	+0.089	.006	5	view →
STAD	All	All	+0.243	.010	3	view →
KIRP	Female	All	+0.243	.034	1	view →
COAD	Female	II,III,IV	−0.079	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RN7SL850P–BLCA

Open the BLCA breakdown →